Covid-19 vaccine developer AstraZeneca agrees to buy rare disease firm Alexion for $39 billion

A general view of an analytical chemist at AstraZeneca's headquarters in Sydney, Australia. AstraZeneca agreed to buy Boston pharmaceutical firm Alexion for $39 billion.

Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion for $39 billion.

The acquisition is one of the largest deals of the year for the drug industry and would expand AstraZeneca's reach in rare diseases. Alexion has an immunology unit in Boston that serves patients with rare disorders.

(0) comments

Welcome to the discussion.

Please log in, or sign up for a new, free account to read or post comments.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.